# CCND1

Source: https://onco.cc/targets/ccnd1/  
OnCo record `ccnd1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Skin cancer, Multiple myeloma and 5 more.

## Summary

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.

CIViC holds 23 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Tamoxifen, Ribociclib and Sorafenib and others. Open Targets scores its association with cancer at 0.86 (direct and indirect evidence; datatypes clinical 0.97, genetic literature 0.61, affected pathway 0.80, literature 1.00, genetic association 0.70, somatic mutation 0.93, animal model 0.56). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Head and Neck Squamous Cell Carcinoma, Plasma Cell Myeloma, Endometrial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cyclin D1; G1/S-specific cyclin-D1; U21B31; BCL1; D11S287E; PRAD1
- Tags: cancer-genes-wave
- Symbol: CCND1
- Class: transcription
- Biology: Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also a substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Location: Nucleus; Cytoplasm; Nucleus membrane (UniProt). Locus 11q13.3 (HGNC).
- Where found: Breast cancer: Open Targets association 0.75 with breast cancer (MONDO_0007254); CIViC evidence names this disease; Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898); Multiple myeloma: Open Targets association 0.53 with plasma cell myeloma (MONDO_0009693); CIViC evidence names this disease; Ovarian cancer: CIViC evidence names this disease; Head and neck squamous cell carcinoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (HNSC); Renal cell carcinoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 23 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene; UniProt keyword "DNA damage". Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Childhood B-cell Acute Lymphoblastic Leukaemia; Anaplastic Thyroid Carcinoma.

## Sources

- HGNC HGNC:1582: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1582
- UniProt P24385: https://www.uniprot.org/uniprotkb/P24385/entry
- NCBI Gene 595: https://www.ncbi.nlm.nih.gov/gene/595
- Ensembl ENSG00000110092: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110092

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ccnd1.json